col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


66 Results       Page 1

 [1] 
Springer-Verlag: PharmacoEconomics & Outcomes News
  original article Date Title Authors   All Authors
1 [GO] 2021―Nov―26 Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
2 [GO] 2021―Nov―12 NZ's Pharmac negotiates deal for Roche's monoclonal antibodies for COVID-19
3 [GO] 2021―Nov―12 NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
4 [GO] 2021―Nov―12 Counting the cost of COVID-19 at the peak of the pandemic in Spain
5 [GO] 2021―Nov―12 Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA
6 [GO] 2021―Nov―12 Remote pulse-ox monitoring for COVID-19 patients saves costs, improves outcomes in the USA
7 [GO] 2021―Oct―29 Productivity losses impact cost effectiveness of COVID-19 vaccine
8 [GO] 2021―Oct―16 COVID-19 a substantial burden for hospitals and patients in the USA
9 [GO] 2021―Oct―16 NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
10 [GO] 2021―Oct―16 UK's NICE updates COVID-19 guideline to include monoclonal antibody recommendations
11 [GO] 2021―Oct―16 Testing and restrictions are cost-effective COVID-19 measures
12 [GO] 2021―Oct―16 Estimated direct costs of COVID-19 pandemic high in Turkey, but true costs "undoubtedly higher"
13 [GO] 2021―Oct―16 Payments ≥$US500 would incentivise 50% of US people uncertain about COVID-19 vaccination
14 [GO] 2021―Oct―01 NZ's Pharmac to fund tocilizumab for moderate-to-severe cases of COVID-19
15 [GO] 2021―Sep―03 Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
16 [GO] 2021―Sep―03 ICER publishes draft scoping report on COVID-19 treatments
17 [GO] 2021―Aug―20 Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
18 [GO] 2021―Aug―07 UK's NICE issues guideline on diagnosing rare COVID-19 vaccination-related blood clots
19 [GO] 2021―Jul―23 NICE to publish guidelines for rare blood clotting syndrome from COVID-19 vaccination
20 [GO] 2021―Jul―10 COVID-19 lockdown increased diabetic mortality, morbidity and costs in Italy
21 [GO] 2021―Jul―10 Costs of ICU care during COVID-19 pandemic in USA
22 [GO] 2021―Jul―10 Best COVID-19 vaccine allocation strategy using a net-monetary benefit approach?
23 [GO] 2021―Jul―10 COVID-19-related decreases in paediatric PCV 13 use does not justify vaccination of older adults
24 [GO] 2021―Jun―26 Pfizer COVID-19 vaccine recommended for pregnant women in Australia and New Zealand
25 [GO] 2021―Jun―11 COVID-19 pandemic associated with substantial costs in older Medicare beneficiaries
26 [GO] 2021―Jun―11 Economic impact of avoidable cancer deaths due to COVID-19 pandemic 'substantial'
27 [GO] 2021―May―28 Expediting COVID-19 vaccination increases QALYs and saves costs in the USA
28 [GO] 2021―May―28 Tocilizumab cost effective in reducing COVID-19-related deaths
29 [GO] 2021―Apr―30 Remdesivir cost effective for severe COVID-19 in China
30 [GO] 2021―Apr―30 NICE COVID-19 rapid guidelines
31 [GO] 2021―Apr―16 COVID-19 QALY values differ between US EQ-5D-5L value sets
32 [GO] 2021―Apr―16 Easing of COVID-19 social restrictions in England comes at a cost
33 [GO] 2021―Apr―02 Willingness to pay for COVID-19 vaccination in China
34 [GO] 2021―Apr―02 Predicted uptake of COVID-19 vaccination in USA
35 [GO] 2021―Mar―19 Cost-effectiveness framework for evaluating COVID-19 therapies
36 [GO] 2021―Mar―19 Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
37 [GO] 2021―Mar―19 Home-based rapid SARS-CoV-2 antigen testing reduces transmission, saves lives at reasonable cost
38 [GO] 2021―Mar―19 Australians willing to accept short-term restrictions during pandemic
39 [GO] 2021―Mar―05 Rapid COVID-19 movement restrictions reduce societal costs
40 [GO] 2021―Mar―05 WTP for COVID-19 vaccine in Chile
41 [GO] 2021―Feb―05 COVID-19 vaccination predicted to be cost effective in USA
42 [GO] 2021―Jan―22 ICU bed reserve capacity for COVID-19 cost effective in Germany
43 [GO] 2021―Jan―22 SARS-CoV-2 testing with saliva versus nasopharyngeal swabs: similar sensitivity, lower cost
44 [GO] 2021―Jan―08 Effects on LOS may not justify cost of remdesivir for severe COVID-19
45 [GO] 2021―Jan―08 Cost effective COVID-19 mitigation measures in US colleges
46 [GO] 2021―Jan―08 Public's willingness to wait for COVID-19 vaccine
47 [GO] 2021―Jan―08 National lockdown not cost effective in Israel during COVID-2 pandemic
48 [GO] 2020―Nov―27 ICER's second update to pricing models of remdesivir for COVID-19
49 [GO] 2020―Nov―27 COVID-19 control strategies cost effective in South Africa
50 [GO] 2020―Oct―30 Factors affecting COVID-19 vaccine acceptability in the US
51 [GO] 2020―Oct―30 Early, effective response to COVID-19 will reduce large resource needs
52 [GO] 2020―Oct―16 HTA assessment of COVID-19 interventions in Ireland
53 [GO] 2020―Oct―02 Expanded testing for COVID-19 could be cost effective in USA
54 [GO] 2020―Oct―02 Costs of active COVID-19 testing in Canada
55 [GO] 2020―Aug―21 Cost-benefit of COVID-19 lockdown in the UK
56 [GO] 2020―Jul―24 Willingness to pay for a COVID-19 vaccine high in Chile
57 [GO] 2020―Jul―10 ICER update to pricing models of remdesivir for COVID-19
58 [GO] 2020―Jul―10 Policy options discussed for pricing novel COVID-19 vaccines/treatment
59 [GO] 2020―Jun―26 OOP burden for COVID-19-like respiratory hospitalisations varies in US
60 [GO] 2020―May―16 Impact of COVID-19 pandemic on HTA
61 [GO] 2020―May―16 COVID-19 testing before endoscopy safe, effective in the US
62 [GO] 2020―May―16 ICER releases pricing models for potential COVID-19 treatments
63 [GO] 2020―May―16 Demand for potentially hazardous COVID-19 treatments
64 [GO] 2020―May―03 Costs vs benefits of tackling COVID-19
65 [GO] 2020―May―03 Substantial direct medical costs for symptomatic COVID-19 cases in the US
66 [GO] 2020―Apr―03 ICER's timelines for assessments extended due to COVID-19
 [1] 

66 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.020 sec